Comera Investor Presentation Deck

Caffeine-based SQore Excipient Optimized to Lower Viscosity for Several Biologics Viscosity (CP) 70 60 50 30 20 10 0 50 Caffeine Control -Arginine -NaCl 75 100 infliximab (mg/mL) Remicade 125 INFLIXIMAB 150 77% viscosity reduction Infliximab formulated in a 20 mM phosphate-acetate buffer at pH 6.0 (control) and in the presence of 75 mM caffeine, 100 mM ArgHCI, or 100 mM NaCl Viscosity (CP) 70 60 50 40 30 20 10 0 100 Comm-Control -PBS-Control Comm-Caffeine -PBS-Caffeine 125 175 150 ipilimumab (mg/mL) (ma/mL) YERVOY (ipilimumab) ( Source: "Caffeine as a viscosity reducer for highly concentrated monoclonal antibody solutions" Journal of Pharmaceutical Sciences 110 (2021) 3594-3604 https://doi.org/10.1016/j.xphs.2021.06.030 200 Comera LIFE SCIENCES 45-78% viscosity reduction 225 Ipilimumab formulated in Yervoy commercial formulation vehicle (Comm.) and PBS with or without 75 mM caffeine 13

View entire presentation